hsCRP
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- hsCRP is the most sensitive blood marker of systemic inflammation — standard CRP tests miss the low-level chronic inflammation that drives long-term disease. Always order the high-sensitivity version.
- Longevity-optimal target: below 0.5 mg/L. Standard labs consider anything below 1.0 mg/L 'low risk.' But at the level of longevity optimization, the lower the better — aim for 0.5 mg/L or less.
- Elevated hsCRP independently predicts cardiovascular events — even in people with normal cholesterol. The JUPITER trial showed statin treatment in people with low LDL but elevated hsCRP significantly reduced heart attacks and strokes.
- hsCRP is highly modifiable. Diet, exercise, sleep, stress reduction, and treatment of underlying conditions (metabolic dysfunction, periodontal disease, sleep apnea) can all lower it meaningfully.
- A single elevated reading isn't definitive. Acute infection, injury, or illness temporarily spikes hsCRP. Always retest after ruling out acute causes before drawing conclusions about chronic inflammation.
Why Inflammation Is a Central Driver of Aging
In the longevity medicine community, the term "inflammaging" has emerged to describe a phenomenon that decades of research have now firmly established: chronic low-grade systemic inflammation is one of the most consistent features of biological aging, and it actively drives the major diseases of later life — cardiovascular disease, type 2 diabetes, Alzheimer's disease, and cancer.
This is not the acute inflammation you experience when you cut your finger or catch a cold — a rapid, localized response that resolves within days. Inflammaging is different: a persistent, low-level activation of the immune system that produces no obvious symptoms but continuously stresses tissues throughout the body. It is detectable in the blood, and hsCRP is its most reliable and clinically validated marker.
A foundational study by Ridker et al. published in the New England Journal of Medicine in 1997 demonstrated that hsCRP predicted future cardiovascular events in apparently healthy women independently of cholesterol levels — a finding that fundamentally changed how cardiologists think about inflammation. 1 Since then, the evidence base connecting hsCRP to long-term disease risk has grown to encompass not just cardiovascular outcomes but metabolic disease, cognitive decline, and all-cause mortality.
The implication for longevity: measuring and managing inflammation is not optional. It is as fundamental to long-term health as managing blood pressure or cholesterol — and for most people, far less attended to.
Standard Reference Ranges vs. Longevity-Optimal Ranges
Clinical cutoffs for hsCRP were developed for cardiovascular risk stratification — specifically for estimating near-term risk of heart attack and stroke. They are not calibrated to minimize the inflammatory burden that accumulates over a lifetime. The longevity-optimal target is considerably more aggressive.
| Category | hsCRP Level | Standard Interpretation | Longevity Assessment |
|---|---|---|---|
| Longevity-optimal | Below 0.5 mg/L | Low risk | Optimal — minimal inflammatory burden |
| Good | 0.5–1.0 mg/L | Low risk | Good — monitor trend over time |
| Monitor | 1.0–3.0 mg/L | Average / moderate risk | Monitor — investigate and intervene |
| Elevated | 3.0–10.0 mg/L | High risk | Elevated — significant intervention needed |
| High / Acute | Above 10.0 mg/L | Possible acute infection/inflammation | High — rule out acute cause, then investigate chronic drivers |
An important caveat: readings above 10 mg/L typically indicate acute infection or injury rather than chronic inflammation, and should be interpreted differently. The meaningful zone for longevity assessment is below 10 mg/L — within this range, the relationship between hsCRP and long-term disease risk is continuous and clinically significant.
Research published in the Archives of Internal Medicine by Pai et al. found that even within the "low risk" clinical category (below 3 mg/L), there was a graded relationship between hsCRP levels and cardiovascular events — suggesting that the standard cutoffs obscure meaningful differences in risk. 2
Already have your lab results? See how your hsCRP and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →How Chronic Inflammation Drives Disease and Aging
Understanding why hsCRP matters requires a working model of what chronic inflammation actually does in the body. C-reactive protein is not itself harmful — it is a downstream signal, a proxy for the cytokines, immune cells, and signaling molecules that constitute the actual inflammatory process. Elevated hsCRP tells you the inflammatory machinery is running when it shouldn't be. The question is what that machinery is doing to your tissues.
The mechanisms are systemic and interconnected:
- Atherosclerosis: Chronic inflammation damages the endothelial lining of blood vessels, promoting the entry of oxidized LDL particles into the vessel wall. This initiates and accelerates plaque formation. Inflammation also destabilizes existing plaques — making them more likely to rupture and cause acute heart attacks and strokes. This is why hsCRP predicts cardiovascular events even in people with "normal" cholesterol.
- Insulin resistance: Inflammatory cytokines, particularly TNF-α and IL-6, directly impair insulin signaling in muscle and liver cells. This creates a bidirectional relationship: metabolic dysfunction drives inflammation, and inflammation worsens metabolic dysfunction. Elevated hsCRP and elevated fasting insulin frequently co-occur and amplify each other.
- Neurodegeneration: The brain is not isolated from systemic inflammation. Inflammatory signals cross the blood-brain barrier and activate resident immune cells called microglia, contributing to the neuroinflammation increasingly recognized as a major driver of Alzheimer's disease and other dementias. Multiple large studies have found elevated midlife hsCRP associated with increased dementia risk decades later.
- Cancer: Chronic inflammation creates a microenvironment that promotes cellular mutation, tumor growth, and suppression of anti-tumor immune responses. Several cancers — including colorectal, lung, and breast cancer — show associations with elevated hsCRP in prospective studies.
- Cellular senescence: Senescent cells — cells that have stopped dividing but haven't been cleared by the immune system — secrete a pro-inflammatory cocktail called the SASP (senescence-associated secretory phenotype). This creates a feedback loop where accumulated senescent cells drive more inflammation, which accelerates further cellular aging.
What unifies these mechanisms is time. A single elevated hsCRP reading is not a crisis. But sustained elevation over years and decades represents a continuous insult to tissues throughout the body — and it is this cumulative burden that the longevity-optimal target is designed to minimize.
What Drives hsCRP Up — and Down
hsCRP is among the most modifiable longevity markers. The drivers of chronic inflammation are well-understood, and most of them are within your control.
Factors that raise hsCRP
- Obesity — particularly visceral adiposity; fat tissue, especially abdominal fat, actively secretes pro-inflammatory cytokines including IL-6, which directly drives hepatic CRP production
- Poor diet — ultra-processed foods, refined carbohydrates, and trans fats all promote systemic inflammation; a diet high in omega-6 fatty acids relative to omega-3 is particularly inflammatory
- Insulin resistance and metabolic syndrome — the inflammatory and metabolic pathways are deeply intertwined; elevated fasting insulin and elevated hsCRP commonly co-occur
- Chronic poor sleep — even a few nights of inadequate sleep meaningfully elevates inflammatory markers; chronic sleep deprivation is one of the most consistent drivers of elevated hsCRP
- Chronic psychological stress — sustained activation of the stress response (via cortisol and sympathetic nervous system pathways) promotes systemic inflammation over time
- Periodontal (gum) disease — one of the most commonly overlooked drivers of chronically elevated hsCRP; the oral microbiome communicates directly with the systemic inflammatory system
- Sedentary behavior — physical inactivity independently promotes inflammation, separate from its effects on body composition
- Smoking — tobacco smoke is a direct pro-inflammatory stimulus and a consistent predictor of elevated hsCRP
- Sleep apnea — untreated sleep apnea drives chronic nocturnal hypoxia and autonomic stress, both of which elevate inflammatory markers
Factors that lower hsCRP
- Weight loss — particularly loss of visceral fat; reducing abdominal adiposity is one of the most powerful interventions for lowering hsCRP
- Regular aerobic exercise — even moderate intensity exercise consistently lowers hsCRP over time through multiple anti-inflammatory mechanisms, including improved insulin sensitivity and adipokine profile
- Mediterranean-style diet — high in vegetables, legumes, olive oil, and oily fish; multiple randomized trials have shown meaningful reductions in hsCRP
- Increasing omega-3 fatty acids (EPA + DHA) — fish oil supplementation or increased oily fish intake shifts the balance toward anti-inflammatory eicosanoids and reliably lowers hsCRP
- Adequate sleep (7–9 hours) — restoring normal sleep architecture reduces inflammatory cytokine production
- Stress management — interventions including mindfulness, yoga, and social connection have demonstrated measurable reductions in inflammatory markers
- Treating underlying conditions — addressing periodontal disease, sleep apnea, and insulin resistance removes major chronic inflammatory inputs
- Statins — reduce hsCRP independently of their lipid-lowering effect, which is the basis of the JUPITER trial finding that statins benefit people with elevated hsCRP even at low LDL levels
The JUPITER Trial — Why hsCRP Changed Cardiology
The landmark JUPITER trial, published in the New England Journal of Medicine in 2008, enrolled nearly 18,000 apparently healthy adults with low LDL cholesterol (below 130 mg/dL) but elevated hsCRP (above 2 mg/L). Half received rosuvastatin; half received placebo.
The trial was stopped early because the statin group showed a 44% reduction in major cardiovascular events. The key insight was not about statins per se — it was about hsCRP. These were patients who would not have been treated under standard lipid-based guidelines. Their LDL was normal. What identified their elevated risk was inflammation, as measured by hsCRP. 3
JUPITER established that hsCRP is not merely a marker but an actionable risk factor — one that identifies a population at meaningful cardiovascular risk who are invisible to conventional lipid-only screening. It is the most compelling evidence for why hsCRP should be part of every cardiovascular risk assessment.
How to Test hsCRP
hsCRP requires a standard blood draw. There are two important things to know about testing it correctly.
First, always specify high-sensitivity CRP — the assay matters. Standard CRP tests are designed for detecting acute infection and have a detection floor around 5–10 mg/L. hsCRP assays detect levels down to 0.1–0.3 mg/L, which is where all the relevant signal for chronic inflammation and cardiovascular risk assessment lives. These are different tests, and standard CRP is essentially useless for longevity monitoring.
Second, avoid testing immediately after acute illness, significant exercise, dental work, or injury — all of these will temporarily elevate hsCRP and give you a false picture of your chronic inflammatory state. A minimum of two weeks after any acute inflammatory event is the standard recommendation before drawing conclusions from a result.
Through a longevity testing service: Function Health, InsideTracker, and Marek Health all include hsCRP as part of their comprehensive panels. This provides the most useful context — seeing hsCRP alongside metabolic markers, lipids, and hormones gives you a complete picture of interrelated risk factors.
À la carte through Ulta Lab Tests: hsCRP can be ordered without a doctor's visit for $15–25 at most US locations, with results in 24–48 hours. Make sure the listing specifies "high-sensitivity" or "cardiac" CRP.
Through your physician: Any primary care physician can order hsCRP. It is increasingly included in cardiovascular risk panels, but may not be part of a standard annual physical — request it specifically if your physician does not routinely include it.
How Often Should You Test?
If your hsCRP is in the longevity-optimal range (below 0.5 mg/L) and you have no ongoing metabolic issues, testing every 6–12 months alongside a full lipid panel is sufficient to confirm stability.
If your hsCRP is elevated and you are actively making dietary, lifestyle, or pharmacological changes, testing every 90 days allows you to measure the response to interventions. Unlike HbA1c, hsCRP can respond to lifestyle changes relatively quickly — improvements in diet, exercise, and sleep can lower it within weeks to a few months.
Because hsCRP reflects a single point in time (not a 90-day average like HbA1c), consider testing twice within a few weeks if your initial result is elevated, to rule out an acute cause before concluding you have a chronic inflammatory problem. Always pair hsCRP with ApoB, HbA1c, and fasting insulin for a complete picture of cardiovascular and metabolic risk.
Sources
- Ridker PM, et al. "Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men." New England Journal of Medicine, 1997. PubMed →
- Pai JK, et al. "Inflammatory Markers and the Risk of Coronary Heart Disease in Men and Women." New England Journal of Medicine, 2004. PubMed →
- Ridker PM, et al. "Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein." New England Journal of Medicine, 2008. PubMed →
| Range Type | Value (mg/L) | Notes |
|---|---|---|
| Standard Clinical Range | Below 3.0 mg/L | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | Below 0.5 mg/L |
Associated with reduced all-cause mortality and extended healthspan.
Standard clinical cutoffs flag hsCRP above 3.0 mg/L as high cardiovascular risk. Longevity medicine targets below 0.5 mg/L — a level associated with minimal inflammatory burden and significantly lower long-term disease risk across multiple organ systems.
|
Already have your results? See what your hsCRP and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What is a good hsCRP level for longevity?
For longevity optimization, the target hsCRP is below 0.5 mg/L. Standard clinical guidelines classify anything below 1.0 mg/L as low cardiovascular risk, and below 3.0 mg/L as moderate risk. But at the level of longevity medicine, below 0.5 mg/L is the goal — this level reflects minimal chronic inflammatory burden, which is associated with meaningfully better long-term outcomes across cardiovascular, metabolic, and neurological health.
What is the difference between CRP and hsCRP?
Standard CRP tests are designed to detect acute inflammation — they have a lower detection limit of around 5–10 mg/L, which makes them useful for diagnosing infections or inflammatory conditions but blind to the chronic low-grade inflammation that drives long-term disease. High-sensitivity CRP (hsCRP) uses a more sensitive assay that can detect levels as low as 0.1–0.3 mg/L. This is the version used in cardiovascular risk assessment and longevity medicine. Always specify hsCRP when ordering — a standard CRP result in the 'normal' range tells you essentially nothing about your chronic inflammatory state.
Can hsCRP be elevated without a serious underlying cause?
Yes, and this is important context for interpreting results. hsCRP rises sharply with any acute inflammation — a cold, a dental infection, a minor injury, intense exercise in the 24 hours prior to the test, or even poor sleep the night before can temporarily elevate it. This is why a single elevated reading should never be interpreted in isolation. If your hsCRP is elevated, rule out acute causes first, then retest 2–4 weeks later. If it remains elevated on repeated testing, that pattern is clinically meaningful and warrants investigation.
How does hsCRP connect to cardiovascular risk?
hsCRP predicts cardiovascular risk through multiple mechanisms. Chronic inflammation directly damages the endothelium — the inner lining of blood vessels — creating an environment where atherosclerotic plaques are more likely to form and rupture. Inflammation also makes existing plaques less stable. The landmark JUPITER trial demonstrated that among people with low LDL cholesterol but elevated hsCRP, statin therapy significantly reduced major cardiovascular events — establishing elevated hsCRP as an independent and actionable cardiovascular risk factor, not merely a marker.
Does a standard blood test include hsCRP?
No — hsCRP is not part of a standard metabolic panel or annual bloodwork. You need to specifically request it. It is included in comprehensive longevity panels from Function Health, InsideTracker, and Marek Health, and can be ordered directly through Ulta Lab Tests for $15–25 without a doctor's visit. Make sure to request hsCRP specifically — standard CRP is a different, less sensitive test.